Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)

NCT01300455 | Completed Phase 1 Results

• 1 other identifier: 4305-036
• Study Type: interventional
• Target: 26
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with mild to moderate obstructive sleep apnea (OSA) compared to administration of placebo. The primary hypothesis of this study is that multiple doses of MK-4305 do not produce a clinically significant increase in Apnea-Hypopnea Index (AHI) in participants with mild to moderate OSA, as compared to placebo.

Conditions

Sleep Apnea

Keywords

Insomnia; obstructive sleep apnea; orexin receptor antagonist

Outcome Measures

Primary Outcomes (3)

• Mean Apnea-Hypopnea Index (AHI)

  Evaluation of the effect of multiple dose administration of suvorexant on AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to \<15/hr and moderate OSA = 15 to \<30/hr.

  Day 4

• Number of Participants With an Adverse Event

  An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

  Up to 14 days after last dose

• Number of Participants Who Discontinued Study Drug Due to an AE

  An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

  Up to 13 days

Secondary Outcomes (4)

• Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time

  Day 1 and Day 4

• Percentage of Total Sleep Time That Arterial SaO2 is Less Than 90%, 85%, and 80%

  Day 1 and Day 4

• Mean Arterial SaO2 for Different Sleep Stages

  Day 1 and Day 4

• Mean AHI

  Day 1

Study Arms (2)

Suvorexant (40 mg)

EXPERIMENTAL

In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.

Drug: Suvorexant; Drug: Matching Placebo

Placebo

PLACEBO COMPARATOR

In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.

Drug: Suvorexant; Drug: Matching Placebo

Interventions

Suvorexant DRUG

40 mg tablets, orally once daily for 4 consecutive days in the evening

Also known as: MK-4305, SCH 900433

Placebo; Suvorexant (40 mg)

Matching Placebo DRUG

Placebo tablets, orally once daily for 4 consecutive days in the evening

Placebo; Suvorexant (40 mg)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female participants of reproductive potential must demonstrate a serum β-human chorionic gonadotrophin (hCG) level consistent with the nongravid state at the pre-study (screening) visit and agree to use (and/or have their partner use) two (2) acceptable methods of birth control beginning at the pre-study visit throughout the study.
• Women who are postmenopausal without menses for at least 1 year and a follicle stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation, and/or are status post hysterectomy, oophorectomy or tubal ligation may participate.
• Participants with a Body Mass Index (BMI) ≤40 kg/m2 at the pre-study (screening) visit.
• Participants have to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests.
• Participants without clinically significant abnormality on electrocardiogram (ECG) performed at the pre-study (screening) visit and/or prior to administration of the initial dose of study drug.
• Participants have an International Classification of Sleep Disorders diagnosis of OSA.
• Participants have confirmed mild or moderate OSA (defined as mild
• OSA with AHI ≥5 and \<15, and moderate OSA with AHI ≥15 and \<30) based on the screening nighttime polysomnography (NPSG).
• Participants have a usual bedtime between 20:00 (8:00 post meridiem \[PM\]) and 00:30 (12:30 ante meridiem \[AM)\] and is not subject to any other unusual changes in sleeping routine and sleeps for 4 hours or more per night.
• Participants must complete a sleep history diary for at least 5 consecutive days and up to 21 days prior to the screening PSG visit.
• Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months; participants who have discontinued smoking or the use of nicotine/nicotine containing products for at least approximately 3 months may be enrolled in the study at the discretion of the investigator.

You may not qualify if:

• Participants have used continuous positive airway pressure devise (CPAP) or a dental appliance within the preceding 7 days prior to screening NPSG Visit, or is required to use CPAP or a dental appliance during course of the study (7 days prior to the screening NPSG, throughout the study \[including washout intervals between treatment periods\], and until the poststudy visit).
• Participants have other than OSA and evidence of another clinically significant, active pulmonary disorder such as bronchiectasis, emphysema, or asthma documented by history, physical examination, or chest x-ray.
• Participant have either a history within the past 6 months prior to the prestudy visit or current evidence of an unstable or clinically significant cardiovascular disorder, including but not limited to acute coronary syndrome, unstable angina, congestive heart failure, cardiogenic syncope, cardiomyopathy, any symptomatic arrhythmia, orthostatic hypotension, or uncontrolled hypertension.
• Participants have abnormal pre-randomization laboratory values other clinically significant, unexplained laboratory abnormality in the opinion of the investigator with alanine transaminase (ALT) \>1.5 x the upper limit of normal (x ULN), aspartate transaminase (AST) \>1.5 x ULN, total bilirubin \>1.5 x ULN, or serum creatinine of \>2 mg/dL.
• Participants have a history or diagnosis of narcolepsy, cataplexy (familial or idiopathic), circadian rhythm sleep disorder, parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder, periodic limb movement (PLM) disorder, restless legs syndrome, or primary hypersomnia.
• Participants have a screening PSG recording with oxygen (O2) saturation \<80% for ≥5% of the total sleep time, and \>10 PLM per hour associated with an arousal (periodic limb movement arousal index \[PLMAI\]).
• Participant is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last 5 to 10 years. Participant who have had situational depression may be enrolled in the study at the discretion of the investigator.
• Participant has lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder; or, a psychiatric condition requiring treatment with a prohibited medication; or, other psychiatric condition that, in the investigator's opinion, would interfere with the participant's ability to participate in the study.
• Participant, in the opinion of the investigator, has a history or current evidence of any condition, therapy, lab or ECG abnormality or other circumstances that might confound the results of the study, or interfere with the participant's participation for the full duration of the study.
• Participant has any history of a neurological disorder, including but not limited to seizure disorder (other than single episodes of childhood febrile seizures), stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness within the last 10 years.
• Participant has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases. Participants with a history of uncomplicated kidney stones may be enrolled in the study at the discretion of the investigator.
• Participant has a history of neoplastic disease except: 1. adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the study; 2. participants with other malignancies which have been successfully treated ≥10 years prior to the prestudy (screening) visit where, in the judgment of both the Investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the prestudy (screening) visit, or 3. participants, who, in the opinion of the Investigator, are highly unlikely to sustain a recurrence for the duration of the study.
• Participant is a nursing mother.
• Participant has a positive screening urine alcohol test or drug test.
• Participant has a need for more than 3 toilet visits during the night.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (1)

• Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.

  PMID: 26194728 RESULT

MeSH Terms

Conditions

Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders; Sleep Apnea, Obstructive

Interventions

suvorexant

Condition Hierarchy (Ancestors)

Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 17, 2011
• First Posted: February 21, 2011
• Study Start: March 19, 2011
• Primary Completion: August 11, 2011
• Study Completion: August 11, 2011
• Last Updated: September 21, 2018
• Results First Posted: August 29, 2014

Record last verified: 2018-08

Data Sharing

• IPD Sharing: Will share